OncoMatch/Clinical Trials/NCT06802835
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Is NCT06802835 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including EGFR Antibody and PD-1 antibody for nasopharyngeal cancinoma (npc).
Treatment: EGFR Antibody · PD-1 antibody · Gemcitabine, Cisplatin — This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment; At least 1 measurable lesion that meets RECIST 1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
WBC≥3.0×10^9/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct)
Kidney function
BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula)
Liver function
TBIL≤2.0×ULN, ALT, AST≤2.5×ULN
Cardiac function
The myocardial enzyme spectra were in the normal range; Uncontrolled cardiovascular disease: Grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); Patients with grade III-IV cardiac insufficiency according to NYHA standards, or left ventricular ejection fraction (LVEF) <50% indicated by cardiac color ultrasound; Myocardial infarction within 1 year [excluded]
Blood routine examination standards should meet: WBC≥3.0×10^9/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct); Biochemical tests should meet the following criteria: TBIL≤2.0×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula); Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as PT is within the intended range of anticoagulant drug use; The myocardial enzyme spectra were in the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify